Pfiz­er nabs eq­ui­ty stake in Swiss biotech work­ing on celi­ac ther­a­py; Verona gets more cash af­ter COPD win

Pfiz­er is in­vest­ing in new treat­ments for celi­ac dis­ease.

The Big Phar­ma shelled out $35 mil­lion in eq­ui­ty for Anokion, a Swiss biotech shoot­ing for a celi­ac ther­a­py. Anokion in­tends to use the mon­ey to fund Phase II stud­ies for the can­di­date, known as KAN-101 and ac­quired in a 2019 buy­out of Astel­las-backed Kanyos Bio. Pfiz­er al­so gets a seat each on Anokion’s board of di­rec­tors and sci­en­tif­ic ad­vi­so­ry board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER